-
-
Small Molecule Drug Platforms
-
Chiral Catalysis Technology
-
Continuous Flow Technology
-
Fluorine Chemistry
-
Enzyme Catalysis
-
Photocatalysis
-
Solid-State Research
显示更多 -
-
Drug Product (DP) Platforms
-
Sustained and Controlled Release
-
Solubility Enhancement
-
Topical Formulation
-
Liquid Formulation
-
Softgels
-
Oral Fast Dissolving Technology
显示更多 -
-
Peptide Platforms
显示更多 -
Research Team
-
Zhejiang Raybow and Raybow (Suzhou) Achieve CDP A-List Ratings
Release time:
2026-02-04
Recently, Zhejiang Raybow Pharmaceutical Co., Ltd. and Raybow (Suzhou) Pharmaceutical Co., Ltd., subsidiaries of Zhejiang JiuZhou Pharma Co., Ltd., updated their annual ratings on CDP (the global environmental disclosure platform). Both companies delivered outstanding performance, demonstrating internationally leading environmental management capabilities.

About CDP
CDP operates a global, independent environmental disclosure system. CDP ratings are widely recognized as the global “gold standard” for corporate environmental transparency and environmental management, covering three key environmental themes: climate change, water security, and forests.
In 2025, more than 22,100 companies reported environmental data through CDP, with nearly 20,000 companies receiving scores. CDP works with over 640 institutional investors—representing USD 127 trillion in assets under management—as well as hundreds of purchasing organizations, leveraging the influence of investors and buyers to encourage companies to disclose and manage their environmental impacts.
Safeguarding the Source of Life: The Path to Double-A Water Security
The companies have implemented a systematic approach to water-risk management, including comprehensive assessments of water use, diversification of water sources, and robust water-saving and recycling initiatives, continuously improving water-use efficiency. In parallel, they have advanced process optimization and upgraded reclaimed-water reuse and wastewater treatment technologies, achieving a steady reduction in water-use intensity and promoting harmonious coexistence between operations and regional aquatic ecosystems.
Climate Action: Toward a Net-Zero Future
In the area of climate change, the companies have established a science-based climate risk management framework and obtained Science Based Targets initiative (SBTi) validation. Through the adoption of green chemistry, optimization of the energy mix, improvements in energy efficiency, and expanded use of clean energy, they continue to drive the effective implementation of emissions-reduction goals.
Other News
Business Collaboration
Innovative Drug CDMO Services
Tel: 86-576-85588039 / 86-576-85580090
E-mail: bd@jiuzhoupharma.com
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
Business Collaboration
Innovative Drug CDMO Services
Tel: 86-576-85588039 / 86-576-85580090
E-mail: bd@jiuzhoupharma.com
Established Business Services(API)
Tel: 86-576-88881561
E-mail: bd@jiuzhoupharma.com